CD274 and cervical cancer: Herein, we present a case of a newly diagnosed high-risk, locally advanced cervical cancer patient with PALN metastases and low PD-L1 expression, treated with a combination of tislelizumab, bevacizumab, and chemotherapy, followed by radiotherapy with maintenance therapy.